{"id":11680,"date":"2025-11-13T15:32:28","date_gmt":"2025-11-13T14:32:28","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/"},"modified":"2025-11-13T15:32:30","modified_gmt":"2025-11-13T14:32:30","slug":"le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/","title":{"rendered":"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III"},"content":{"rendered":"
\n
\n
\n
\n<\/figure><\/div>\n<\/div>\n

La phase III r\u00e9sulte d’un essai clinique d’un vaccin conjugu\u00e9 contre la typho\u00efde (TCV), EuTYPH-C Inj. Les doses multiples d\u00e9montrent qu’il est s\u00fbr et immunog\u00e8ne dans les populations end\u00e9miques de la typho\u00efde en Afrique subsaharienne. EuTYPH-C Inj. Multi-dose est fabriqu\u00e9 par EuBiologics Co., LTD, R\u00e9publique de Cor\u00e9e.<\/p>\n

L’\u00e9tude, publi\u00e9e dans The Lancet Sant\u00e9 mondiale<\/i>a \u00e9t\u00e9 men\u00e9e sur des sites au Kenya et au S\u00e9n\u00e9gal chez des adultes, des enfants et des nourrissons en bonne sant\u00e9, et a \u00e9valu\u00e9 l’innocuit\u00e9 et la non-inf\u00e9riorit\u00e9 d’EuTYPH-C Inj. Multi-dose compar\u00e9 \u00e0 un comparateur pr\u00e9qualifi\u00e9 de l’Organisation mondiale de la sant\u00e9 (OMS), TCV, Typbar TCV.<\/p>\n

L’\u00e9tude a \u00e9galement \u00e9valu\u00e9 la co-administration d’EuTYPH-C Inj. Multidoses de vaccins contre la rougeole, la rub\u00e9ole et la fi\u00e8vre jaune entre 9 et 12 mois et taux d\u2019anticorps sur six mois.<\/p>\n

R\u00e9sultats en mati\u00e8re de s\u00e9curit\u00e9 et de r\u00e9ponse immunitaire<\/h2>\n

\u00ab\u00a0La s\u00e9curit\u00e9 est d’une importance primordiale lors de l’\u00e9valuation d’un nouveau vaccin. EuTYPH-C Inj. Multi-dose s’est av\u00e9r\u00e9 bien tol\u00e9r\u00e9 dans tous les groupes d’\u00e2ge, avec un profil de s\u00e9curit\u00e9 similaire \u00e0 celui du vaccin de comparaison\u00a0\u00bb, d\u00e9clare Patricia Njuguna, m\u00e9decin-chef et chef de projet de l’\u00e9tude chez PATH. \u00ab\u00a0Aucun probl\u00e8me de s\u00e9curit\u00e9 n’a \u00e9t\u00e9 identifi\u00e9, et aucun \u00e9v\u00e9nement ind\u00e9sirable grave li\u00e9 \u00e0 la vaccination n’a \u00e9t\u00e9 not\u00e9.\u00a0\u00bb<\/p>\n

L’immunog\u00e9nicit\u00e9, qui mesure la r\u00e9ponse immunitaire de l’organisme, a \u00e9t\u00e9 \u00e9valu\u00e9e chez des participants \u00e2g\u00e9s de 9 \u00e0 12 mois. R\u00e9ponses immunitaires aux pr\u00e9sentations \u00e0 dose unique et multidose d’EuTYPH-C Inj. Les doses multiples n’\u00e9taient pas inf\u00e9rieures au Typbar TCV 28 jours apr\u00e8s la vaccination.<\/p>\n

Les taux de s\u00e9roconversion \u00e9taient \u00e9lev\u00e9s 28 jours apr\u00e8s la vaccination et restaient \u00e9lev\u00e9s six mois apr\u00e8s la vaccination. De plus, la co-administration d\u2019EuTYPH-C Inj. L\u2019administration de doses multiples avec d\u2019autres vaccins infantiles n\u2019a pas interf\u00e9r\u00e9 avec les r\u00e9ponses immunitaires aux diff\u00e9rents agents pathog\u00e8nes.<\/p>\n

Implications pour l\u2019acc\u00e8s et l\u2019approvisionnement en vaccins<\/h2>\n

\u00ab Ces r\u00e9sultats constituent une \u00e9tape positive vers notre objectif de fournir un vaccin s\u00fbr et efficace pour pr\u00e9venir la typho\u00efde dans les zones end\u00e9miques. Ce sont des donn\u00e9es cruciales qui ont soutenu l’autorisation du minist\u00e8re cor\u00e9en de la s\u00e9curit\u00e9 alimentaire et pharmaceutique et soutiendront la pr\u00e9qualification de l’OMS, qui est notre prochaine \u00e9tape pour ce vaccin \u00bb, a d\u00e9clar\u00e9 Youngjin Choi, directeur g\u00e9n\u00e9ral de la division de d\u00e9veloppement clinique, EuBiologics Co., LTD.<\/p>\n

\u00ab Nous nous f\u00e9licitons des r\u00e9sultats de cet essai et sommes impatients de fournir EuTYPH-C Inj. Multi-dose aux pays o\u00f9 le fardeau de la typho\u00efde est \u00e9lev\u00e9.<\/p>\n

La pr\u00e9qualification de l’OMS est une d\u00e9signation qui garantit qu’un vaccin r\u00e9pond \u00e0 des normes internationales strictes de qualit\u00e9, de s\u00e9curit\u00e9 et d’efficacit\u00e9 et qui permet qu’il soit achet\u00e9 par les agences des Nations Unies et Gavi, l’Alliance du vaccin.<\/p>\n

Il existe actuellement quatre produits TCV pr\u00e9qualifi\u00e9s, dont deux sont disponibles pour les pays \u00e9ligibles \u00e0 Gavi. Des produits suppl\u00e9mentaires provenant de divers fabricants contribuent \u00e0 faire baisser les prix des vaccins, \u00e0 maintenir un approvisionnement solide et sain et \u00e0 accro\u00eetre l\u2019acc\u00e8s.<\/p>\n

Demande mondiale et perspectives d\u2019avenir<\/h2>\n

\u00ab La demande de VTC dans les pays d’end\u00e9mie typho\u00efde \u00e9ligibles \u00e0 Gavi a \u00e9t\u00e9 \u00e9lev\u00e9e. \u00c0 ce jour, sept pays \u00e9ligibles \u00e0 Gavi ont introduit le VTC, et plusieurs autres sont \u00e0 diverses \u00e9tapes du processus de planification et d’introduction \u00bb, explique le Dr Emmanuel Mugisha, directeur mondial de la mise en \u0153uvre des vaccins et directeur de TyVAC chez PATH, un consortium qui vise \u00e0 acc\u00e9l\u00e9rer l’introduction des VTC dans les pays d’end\u00e9mie typho\u00efde.<\/p>\n

\u00ab\u00a0Le potentiel d’un produit suppl\u00e9mentaire contribuera \u00e0 garantir un approvisionnement stable en vaccins pour les pays int\u00e9ress\u00e9s \u00e0 introduire le TCV dans le cadre de leurs plans de pr\u00e9vention et de contr\u00f4le de la typho\u00efde.\u00a0\u00bb<\/p>\n

Cette \u00e9tude a recrut\u00e9 3\u00a0219 participants en bonne sant\u00e9 \u00e2g\u00e9s de 6 mois \u00e0 45 ans sur deux sites d’\u00e9tude \u00e0 Kericho, au Kenya, et \u00e0 Sandiara, au S\u00e9n\u00e9gal.<\/p>\n

Les partenaires de l’\u00e9tude comprenaient PATH, EuBiologics Co., LTD, le Kenya Medical Research Institute (KEMRI)-Walter Reed Army Institute of Research (WRAIR) Kericho et l’Institut de Recherche en Sant\u00e9, de Surveillance Epid\u00e9miologique et de Formation (IRESSEF).<\/p>\n

\t\t\t\t\t\t\t\t\t\t\t\tFourni par CHEMIN<\/p>\n

<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

La phase III r\u00e9sulte d’un essai clinique d’un vaccin conjugu\u00e9 contre la typho\u00efde (TCV), EuTYPH-C<\/p>\n","protected":false},"author":1,"featured_media":11681,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[7662,90,44,725,732,1067,7664,7663,441,448,5699,47,323],"class_list":["post-11680","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-conjugue","tag-contre","tag-dans","tag-demontre","tag-essai","tag-forte","tag-iii","tag-immunogenicite","tag-phase","tag-securite","tag-typhoide","tag-une","tag-vaccin","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"\nLe vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"La phase III r\u00e9sulte d’un essai clinique d’un vaccin conjugu\u00e9 contre la typho\u00efde (TCV), EuTYPH-C\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-13T14:32:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-13T14:32:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/11\/1763044348_Le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1359\" \/>\n\t<meta property=\"og:image:height\" content=\"906\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III\",\"datePublished\":\"2025-11-13T14:32:28+00:00\",\"dateModified\":\"2025-11-13T14:32:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/\"},\"wordCount\":795,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/11\/1763044348_Le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite.jpg\",\"keywords\":[\"conjugu\u00e9\",\"contre\",\"dans\",\"d\u00e9montre\",\"essai\",\"forte\",\"III\",\"immunog\u00e9nicit\u00e9\",\"phase\",\"s\u00e9curit\u00e9\",\"typho\u00efde\",\"une\",\"vaccin\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/\",\"name\":\"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/11\/1763044348_Le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite.jpg\",\"datePublished\":\"2025-11-13T14:32:28+00:00\",\"dateModified\":\"2025-11-13T14:32:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/11\/1763044348_Le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/11\/1763044348_Le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite.jpg\",\"width\":1359,\"height\":906,\"caption\":\"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d'informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/","og_locale":"fr_FR","og_type":"article","og_title":"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III - RVH-Synergie.org","og_description":"La phase III r\u00e9sulte d’un essai clinique d’un vaccin conjugu\u00e9 contre la typho\u00efde (TCV), EuTYPH-C","og_url":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/","og_site_name":"RVH-Synergie","article_published_time":"2025-11-13T14:32:28+00:00","article_modified_time":"2025-11-13T14:32:30+00:00","og_image":[{"width":1359,"height":906,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/11\/1763044348_Le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III","datePublished":"2025-11-13T14:32:28+00:00","dateModified":"2025-11-13T14:32:30+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/"},"wordCount":795,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/11\/1763044348_Le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite.jpg","keywords":["conjugu\u00e9","contre","dans","d\u00e9montre","essai","forte","III","immunog\u00e9nicit\u00e9","phase","s\u00e9curit\u00e9","typho\u00efde","une","vaccin"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/","url":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/","name":"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/11\/1763044348_Le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite.jpg","datePublished":"2025-11-13T14:32:28+00:00","dateModified":"2025-11-13T14:32:30+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/11\/1763044348_Le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/11\/1763044348_Le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite.jpg","width":1359,"height":906,"caption":"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/le-vaccin-conjugue-contre-la-typhoide-demontre-une-forte-securite-et-immunogenicite-dans-un-essai-de-phase-iii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"Le vaccin conjugu\u00e9 contre la typho\u00efde d\u00e9montre une forte s\u00e9curit\u00e9 et immunog\u00e9nicit\u00e9 dans un essai de phase III"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d'informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/11680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=11680"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/11680\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/11681"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=11680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=11680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=11680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}